Astrocytic tumors

Recent Results in Cancer Research

Volumn 171, Issue , 2009, Pages 3-24

  Riemenschneider, Markus J ^a   Reifenberger, Guido ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; ANTIBIOTIC AGENT; ANTIESTROGEN; ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; DEFOROLIMUS; ENZASTAURIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; SCH 66366; SEMAXANIB; TAMOXIFEN; TANDUTINIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; VATALANIB; WORTMANNIN;

ASTROCYTE; ASTROCYTIC GLIOMA; ASTROCYTOMA; BRAIN TUMOR; CANCER GROWTH; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; ANIMAL; CANCER INVASION; CHEMISTRY; DISEASE MODEL; GENETICS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM INVASIVENESS; SIGNAL TRANSDUCTION;

EID: 67449089555     PISSN: 00800015     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-31206-2_1     Document Type: Review

References (24)

1. Actor B, Cobbers JM, Buschges R et al. (2002) Comprehensive analysis of genomic alterations in gliosarcoma and its two tissue components. Genes Chromosomes Cancer 34:416-427
2. Bailey P, Cushing H (1926) A classification of tumors of the glioma group on a histogenetic basis with a correlated study of prognosis. Lippincott, Philadelphia
3. Balss J, Meyer J, Mueller W et al. (2008) Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol 116:597-602.
4. Bao S, Wu Q, McLendon RE et al. (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760
5. Begemann M, Fuller GN, Holland EC (2002) Genetic modeling of glioma formation in mice. Brain Pathol 12:117-132
6. Beier D, Hau P, Proescholdt M et al. (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015
7. Bell DW, Lynch TJ, Haserlat SM et al. (2005) Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092
8. Bigner SH, Vogelstein B (1990) Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. Brain Pathol 1:12-18
9. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4:335-348
10. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061-1068.
11. CBTRUS (2005) Statistical Report: Primary Brain Tumors in the United States, 1998-2002. Published by the Central Brain Tumor Registry of the United States
12. Chan JA, Zhang H, Roberts PS et al. (2004) Pathogenesis of tuberous sclerosis subependymal subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation. J Neuropathol Exp Neurol 63:1236-1242
13. Choi HS, Wang Z, Richmond W et al. (2006a) Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 2. Bioorg Med Chem Lett 16:2689-2692
14. Choi HS, Wang Z, Richmond W et al. (2006b) Design and synthesis of 7H-pyrrolo[2,3-d]pyrimidines as focal adhesion kinase inhibitors. Part 1. Bioorg Med Chem Lett 16:2173-2176
15. Ekstrand AJ, James CD, Cavenee WK et al. (1991) Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172
16. Eskens FA, Dumez H, Hoekstra R et al. (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917-926
17. Esteller M, Garcia-Foncillas J, Andion E et al. (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
18. Faury D, Nantel A, Dunn SE et al. (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25:1196-1208
19. Fleming TP, Saxena A, Clark WC et al. (1992) Amplification and/or overexpression of plateletderived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res 52:4550-4553
20. Friedlander DR, Zagzag D, Shiff B et al. (1996) Migration of brain tumor cells on extracellular matrix proteins in vitro correlates with tumor type and grade and involves alphaV and beta1 integrins. Cancer Res 56:1939-1947
21. Galanis E, Buckner JC, Maurer MJ et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23:5294-5304 (Pubitemid 46206983)
22. Gerson SL (2004) MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4:296-307
23. Giannini C, Scheithauer BW, Burger PC et al. (1999) Pleomorphic xanthoastrocytoma: what do we really know about it? Cancer 85:2033-2045
24. Giannini C, Hebrink D, Scheithauer BW, Dei Tos AP and James CD (2001) Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma. Neurogenetics 3:159-162